Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYAD NASDAQ:IDYA OTCMKTS:NWPHF NASDAQ:PHAS NASDAQ:SRRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad$0.60$0.67$0.46▼$3.07N/AN/AN/A3,009 shsIDYAIDEAYA Biosciences$28.64-1.9%$26.02$13.45▼$32.67$2.56B0.141.41 million shs1.14 million shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/APHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsSRRASierra Oncology$54.99$54.93$14.91▼$55.19$1.34B0.03931,731 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad0.00%0.00%0.00%0.00%0.00%IDYAIDEAYA Biosciences-4.29%+7.87%+13.44%+23.57%-5.44%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SRRASierra Oncology0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad$0.60$0.67$0.46▼$3.07N/AN/AN/A3,009 shsIDYAIDEAYA Biosciences$28.64-1.9%$26.02$13.45▼$32.67$2.56B0.141.41 million shs1.14 million shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/APHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsSRRASierra Oncology$54.99$54.93$14.91▼$55.19$1.34B0.03931,731 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad0.00%0.00%0.00%0.00%0.00%IDYAIDEAYA Biosciences-4.29%+7.87%+13.44%+23.57%-5.44%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SRRASierra Oncology0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad 0.00N/AN/AN/AIDYAIDEAYA Biosciences 2.74Moderate Buy$44.1954.29% UpsideNWPHFNewron Pharmaceuticals 0.00N/AN/AN/APHASPhaseBio Pharmaceuticals 0.00N/AN/AN/ASRRASierra Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CYAD, SRRA, PHAS, IDYA, and NWPHF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025IDYAIDEAYA BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$27.00 ➝ $30.0010/21/2025IDYAIDEAYA BiosciencesNew Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$30.0010/21/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$38.00 ➝ $41.0010/21/2025IDYAIDEAYA BiosciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$62.0010/8/2025IDYAIDEAYA BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IDYAIDEAYA BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/18/2025IDYAIDEAYA BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.009/12/2025IDYAIDEAYA BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$43.00 ➝ $44.009/9/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/9/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $38.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad$200KN/AN/AN/A$0.02 per shareN/AIDYAIDEAYA Biosciences$7M358.59N/AN/A$12.25 per share2.34NWPHFNewron Pharmaceuticals$6.82M24.50N/AN/A$0.21 per share44.57PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00SRRASierra Oncology$300K4,476.00N/AN/A$6.16 per share8.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad-$6.30MN/A0.00∞N/AN/AN/AN/AN/AIDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)NWPHFNewron Pharmaceuticals-$17.63MN/A0.00N/AN/AN/AN/AN/AN/APHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ASRRASierra Oncology-$94.66M-$6.77N/AN/AN/AN/A-111.88%-100.01%N/ALatest CYAD, SRRA, PHAS, IDYA, and NWPHF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/3/2025Q3 2025IDYAIDEAYA Biosciences-$0.12N/AN/AN/A$59.98 millionN/A8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyadN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ASRRASierra OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyadN/AN/AN/AIDYAIDEAYA BiosciencesN/A12.3912.39NWPHFNewron PharmaceuticalsN/AN/AN/APHASPhaseBio PharmaceuticalsN/A0.470.47SRRASierra Oncology0.0221.2721.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyadN/AIDYAIDEAYA Biosciences98.29%NWPHFNewron PharmaceuticalsN/APHASPhaseBio Pharmaceuticals49.02%SRRASierra Oncology99.30%Insider OwnershipCompanyInsider OwnershipCYADCelyad0.94%IDYAIDEAYA Biosciences2.50%NWPHFNewron PharmaceuticalsN/APHASPhaseBio Pharmaceuticals9.90%SRRASierra Oncology44.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad95N/AN/ANot OptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableSRRASierra Oncology10924.42 million13.65 millionOptionableCYAD, SRRA, PHAS, IDYA, and NWPHF HeadlinesRecent News About These CompaniesGSK bolsters cancer pipeline with $1.9bn Sierra Oncology buyOctober 4, 2024 | pharmaphorum.comPNew cancer treatment center breaks ground in ReddingSeptember 25, 2024 | actionnewsnow.comAImplementation of a Novel Pathway to Integrate Palliative and Oncology Care for Patients With Acute Myeloid Leukemia in a Community HospitalSeptember 19, 2024 | ascopubs.orgANew regional cancer center in Redding is called the Sierra Pacific Regional Cancer CenterAugust 21, 2024 | actionnewsnow.comASierra Space eyes IPO market as it braces for a 'profound industrial revolution' in spaceApril 11, 2024 | msn.comSierra Space, valued at $5.3 billion, eyes IPO to 'accelerate the new space economy'April 11, 2024 | aol.comAUsed 2021 GMC Sierra 2500 trucks for sale near meApril 5, 2024 | cars.comCAnemia of InflammationMarch 26, 2024 | nejm.orgNSierra Oncology Inc.February 21, 2024 | thestreet.comSierra Leone Airport, Sierra Leone, Sierra Leone [ SRK / ]February 15, 2024 | prokerala.comP2014 GMC Sierra 1500 specs & colorsFebruary 6, 2024 | cars.comCUsed 2014 GMC Sierra 1500 Denali trucks for sale near meJanuary 5, 2024 | cars.comC2017 GMC Sierra 1500December 17, 2023 | motortrend.comMSafety in Radiation Oncology (SAFRON)December 16, 2023 | iaea.orgI2024 GMC Sierra 2500HDNovember 24, 2023 | driving.caDSierra deputies believe bear mauled woman after she diedNovember 20, 2023 | kcra.comKSierra Coupon for OctoberNovember 9, 2023 | time.comTCompare 6 trims on the 2021 GMC Sierra 1500October 31, 2023 | cars.comCClario presents a three-part webinar series on oncology trial solutionsOctober 31, 2023 | galvnews.comGFDA approves GSK's unique myelofibrosis treatment OjjaaraSeptember 18, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Microsoft 365 Premium Marks the Next Phase of AI MonetizationBy Chris Markoch | October 12, 2025Archer’s Recent String of Victories Signals a New Phase of GrowthBy Jeffrey Neal Johnson | October 22, 2025Why Teradyne Is a Core Play in the AI Hardware BoomBy Jeffrey Neal Johnson | September 28, 2025CYAD, SRRA, PHAS, IDYA, and NWPHF Company DescriptionsCelyad NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.IDEAYA Biosciences NASDAQ:IDYA$28.64 -0.56 (-1.92%) Closing price 04:00 PM EasternExtended Trading$28.66 +0.02 (+0.05%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Newron Pharmaceuticals OTCMKTS:NWPHF$9.36 0.00 (0.00%) As of 10/17/2025Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Sierra Oncology NASDAQ:SRRASierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
